General Information of Drug (ID: DMYHEUA)

Drug Name
ASN007
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD ID
D0D2XQ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular signal-regulated kinase 1 (ERK1) TT1MG9E MK03_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 DOI: 10.1158/1538-7445.AM2015-4693
3 Clinical pipeline report, company report or official report of HaiHe Biopharma.
4 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
5 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
6 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
7 National Cancer Institute Drug Dictionary (drug name JSI1187).
8 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
9 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.